Agrium–The fertilizer producer is guiding first quarter earnings below current Wall Street consensus, saying a late spring season means first quarter will come in just above break-even. Analysts had been predicting first quarter profit of 53 cents per share.
GlaxoSmithKline–The drug maker decided to end a clinical trial involving its MAGE-A3 vaccine, saying it could not find a group of lung cancer patients who might benefit from the treatment. It is continuing to look into possible uses for the vaccine to treat melanoma.
MannKind–MannKind won the recommendation of an FDA panel for approval of its inhaled diabetes drug, citing its effectiveness for type 2 diabetes.
BlackBerry–The smartphone maker ended a licensing deal with T-Mobile, meaning T-Mobile won't be selling BlackBerry products for use on its network when the current contract expires on April 25.
Charter Communications–Charter could re-enter the bidding for Time Warner Cable, according to a Wall Street Journal Report. The financial dynamics of the deal have changed due to a drop in the stock prices of both Comcast and Time Warner Cable. Comcast announced its all-stock deal for Time Warner Cable on February 13.
Amazon.com–The online retailer has rolled out a new service allowing customer returns using metal lockers at various locations, according to the Wall Street Journal. Separately, the company will hold a news conference later today in New York to unveil an update to its video business.
Microsoft–The company is expected to unveil more about its future strategy for Windows today at its "Build" conference in San Francisco.
Myriad Genetics–The drug company will still see Medicare payments for its genetic screening tests cut, but not by as much as first expected.
Urban Outfitters–The retailer is reporting a "low single-digit" drop in first quarter comparable store sales, according to a new SEC filing.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at email@example.com